Products
Tenpoint's YUVEZZI launches to the US commercial market
First and only dual-agent presbyopia-correcting eye drop offers up to 10 hours of miosis with once-daily dosing.
Legal
New Hampshire governor rejects OD laser legislation
House Bill 349 would have permitted optometrists to perform three ophthalmic procedures; reasoning behind veto included concern over surgical training levels.
Research
Study: High-intensity exercise critical for reducing DR
Physical activity also improved peripheral retinal vessel measurements, with benefits peaking around five sessions and 180 minutes per week.
Research
Study: CV risk score identifies future eye disease risk
Pooled Cohort Equations (PCE) score may help identify high-risk patients when preventive measures may protect their vision.
Business
Biogen is purchasing Apellis
With an estimated price tag of $5.6 billion, the acquisition includes the FDA-approved SYFOVRE.
Research
Vascular changes emerge in later MacTel stages
Study findings suggest retinal vascular alterations become more pronounced in advanced disease stages.
Pipeline
FDA grants Orphan Drug Designation to SignaBlok's ROP therapy
TREM-1 inhibitor is designed to selectively target inflammation via a noninvasive delivery; company plans to report preclinical data at ARVO annual meeting.
Pipeline
Viridian releases phase 3 topline data on elegrobart for TED
REVEAL-1 meets primary goals, with the subcutaneous IGF-1R monoclonal antibody showing rapid and clinically meaningful reductions in proptosis and diplopia.
Pipeline
Kodiak reports positive phase 3 data on tarcocimab for DR
Topline findings from the GLOW2 trial indicate Zenkuda’s superiority over sham as company plans for a multi-indication FDA filing.
Pipeline
Lineage Cell Therapeutics launches new CED cell therapy program
Preclinical candidate COR1 is designed as an allogeneic source of corneal endothelial cells to replace damaged cells and restore corneal function.
Research
Could TKI use cause RVO development?
Tyrosine kinase inhibitors may act as an additional risk factor for RVO in patients with existing vascular comorbidities.
Events
Registration opens for Eyes On Myopia 2026
Virtual event kicks off May 9 in partnership with Woo University, offering up to 5 hours of COPE-accredited CE credits.
Business
Cencora to buy EyeSouth Partners' retina division in $1B deal
Deal will integrate the MCO’s retina business into Retina Consultants of America, expanding its nationwide network of affiliate retina practices.
Products
Eyedaptic launches latest version of AI-based smart glasses for AMD
Designed for patients with retinal diseases, the EYE7 is an integrated wearable solution with real-time vision enhancements and a new visual assistant.
Pipeline
Complement Therapeutics begins patient dosing in GA gene therapy trial
Opti-GAIN trial is evaluating a single subretinal injection of CTx-001, an AAV-based gene therapy modulating multiple pathways of the complement system.
Research
TED may cause reduced stromal corneal thickness
Study findings indicate association with layer-specific corneal structural changes.
Research
Study urges alternative tracking for wet AMD poor responders
Structural change tracking indicates subretinal fibrosis may drive vision loss, calling for a shift in patient monitoring.
Pipeline
Positive 24-month data supports the Elios System for glaucoma treatment
Microinvasive, implant-free procedure used excimer laser technology to lower IOP by 20% or greater among 76% of glaucoma and cataract patients
Products
VirtuaLens launches monovision simulation for VR IOL simulator
Immersive virtual reality IOL patient education system allows patients to “try on” lens options in a virtual setting ahead of cataract surgery.
Business